Metastatic Breast Cancer, HER2-positive Breast Cancer
Conditions
Brief summary
The study is being conducted to evaluate the efficacy, safety and tolerability of pyrotinib combination with CDK4/6 Inhibitor SHR6390 in advanced HER2-Positive breast cancer patients who prior trastuzumab-treated.
Interventions
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Jinming Yu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Metastatic HER2-Positive breast cancer prior trastuzumab-treated; 2. 18-70 Years, female; 3. HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline IHC 3+ or IHC 2+ and FISH, SISH or CISH+); 4. Status of hormone receptor is known, Estrogen receptor(ER) or Progesterone receptor(PR) positive is defined as the percentage of cells positive for ER or PR expression ≥ 10%; 5. ECOG performance status 0 or 1; 6. Life expectancy is not less than 12 weeks; 7. At least one measurable lesion according to RECIST 1.1; 8. Patients treated with systemic treatment for advanced / metastatic breast cancer≤1 line; 9. Natural postmenopausal or OFS in Arm A; 10. Adequate function of major organs meets the following requirements (no blood components have been used within 7 days and cell growth factors have been used within 14 days before randomization): * Neutrophils ≥ 1.5×10\^9/L * Platelets ≥ 100×10\^9/L * Hemoglobin ≥ 90g/L * Total bilirubin≤ 1.5 × the upper limit of normal (ULN) * ALT and AST ≤ 2.5 × ULN (ALT and AST≤5×ULN if liver metastasis) * BUN and Cr ≤ 1.5 × ULN * Left ventricular ejection fraction (LVEF) ≥ 50% * QTcF ≤ 470 ms
Exclusion criteria
1. Patients with central nervous system metastasis (Excluding asymptomatic brain metastases or CNS metastases stable by local treatment); 2. Unable to swallow, chronic diarrhea and intestinal obstruction, gastrointestinal absorption disorders that interfere with drug absorption; 3. Patients who received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before admission; those who received anti-tumor endocrine therapy after screening period; 4. Participated in other drug clinical trials within 4 weeks before admission; 5. Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past; 6. Previously received any CDK4/6 inhibitor treatment; 7. Previously received Capecitabine in HR- patients; 8. Patients with other malignant tumors within 5 years or at the same time( except for cured skin basal cell carcinoma and cervical carcinoma in situ); 9. Patients receive any anti-tumor treatments other than the regimen; 10. Have a history of allergies to the drug components of this regimen,; history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, history of organ transplantation; 11. Have severe heart disease; 12. According to the judgement of the researchers, any serious coexisting disease might be harmful to the patient's safety or avoid the patients from accomplishing the treatment(e.g serious hypertension, diabetes, thyroid dysfunction,active infection etc.); 13. Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial; 14. History of neurological or psychiatric disorders, including epilepsy or dementia; 15. Any other situation evaluated by researchers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Overall Response Rate (ORR) | 2 months | ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR. ORR was assessed by the investigator according to RECIST version 1.1 and is based on BOR, which is defined as best response recorded from start of study treatment until disease progression/recurrence or death. Participants needed to have two consecutive assessments of PR or CR to be a responder. Only participants with measurable disease at baseline were included in the analysis of BOR and who did not have any evaluable post-baseline assessments were classified as not evaluable. The ORR will be reported by percentage with each arms and appropriate confidence intervals. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | Up to 3 years | PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first. |
| Overall Survival (OS) | Up to 3 years | Overall Survival (OS), defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication and participants with no post-baseline information were censored at the date of randomization. |
| Survival Rate | 12 months | Survival rate was defined as the time from randomization to 12month, the rate of participants who were alive at the time in total. |
| Clinical Benefit Response (CBR) | 2 months | CBR is percentage of participants with best (confirmed) PR or CR or SD for at least 6 months. PR or CR or SD is according to RECIST version 1.1. |
| Adverse Events (AEs) | Up to 3 years | AEs were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0. In general, AEs are graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE. The type, grade and frequency of AEs will be reported. |
Countries
China
Contacts
Primary ContactJinming Yu, MD
Backup ContactYongsheng Wang, MD
Outcome results
None listed